US Patent

US8092828 — Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Method of Use · Assigned to Celator Pharmaceuticals Inc · Expires 2029-04-01 · 3y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating cancer by administering a fixed ratio of cytarabine and an anthracycline.

USPTO Abstract

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

Drugs covered by this patent

Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3147`	—	Cytarabine

Patent Metadata

Patent number: US8092828
Jurisdiction: US
Classification: Method of Use
Expires: 2029-04-01
Drug substance claim: No
Drug product claim: No
Assignee: Celator Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.